FDA Biosimilar Approval Tracker Shows 30-Plus Products Cleared Since Mid-2024

Competitive pressure on reference product manufacturers is intensifying: the FDA has cleared more than 30 biosimilar products since mid-2024, with the pace accelerating through the first three quarters of 2026 across biologics ranging from insulin analogs to anti-VEGF agents and oncology supportive-care therapies.

The most crowded reference product in the current cycle is denosumab. Biosimilars referencing Prolia and Xgeva now number more than ten approved entries, with products from multiple sponsors cleared between February 2025 and March 2026. For QA directors and supply-chain leads at originator sites, that volume signals sustained formulary substitution pressure and the likelihood of accelerated post-approval manufacturing supplements as biosimilar sponsors scale up commercial production.

The ranibizumab field tells a similar story. Three biosimilars referencing Lucentis received approval between December 2025 and October 2026, including Lucamzi (ranibizumab-blrz), Ranluspec (ranibizumab-hkdz), and Nufymco (ranibizumab-leyk). Sponsors entering late in a crowded reference-product class face tighter differentiation windows, making robust comparability protocols and process validation packages critical to regulatory review timelines.

On the insulin front, three distinct insulin aspart biosimilars referencing NovoLog have now been approved, with Garzulys (insulin aspart-fsan) cleared in July 2026 joining Kirsty and Merilog. Insulin biosimilar manufacturing operates under both 21 CFR Part 211 GMP requirements and the biologics framework, and the convergence of multiple approved products in this class will test sterility assurance and cold-chain process controls across the sector.

Regulatory affairs leads should also note the interchangeability designations embedded in this approval cycle. The FDA granted interchangeable status to aflibercept biosimilars referencing Eylea as early as May 2024, a designation that carries direct implications for pharmacy-level substitution without prescriber intervention and raises the compliance bar for post-market pharmacovigilance commitments.

For plant heads managing biologics fill-finish or upstream cell culture operations, the breadth of this approval wave across pegfilgrastim, filgrastim, tocilizumab, bevacizumab, pertuzumab, omalizumab, ustekinumab, golimumab, and eculizumab reflects a maturing biosimilar pipeline where ICH Q10 pharmaceutical quality system expectations are now standard review criteria rather than aspirational benchmarks.

The next measurable checkpoint is commercial launch uptake data, which will determine whether the approved product count translates into formulary displacement at the scale regulators and payers have projected.

Source: U.S. Food and Drug Administration, Biosimilar Product Information page via FDA.gov, October 28, 2026.